An evaluation of patisiran: a viable treatment option for transthyretin-related hereditary amyloidosis

Milani, P; Mussinelli, R; Perlini, S; Palladini, G; Obici, L

Milani, P (reprint author), Fdn IRCCS Policlin San Matteo, Amyloidosis Res & Treatment Ctr, Viale Golgi 19, I-27100 Pavia, Italy.

EXPERT OPINION ON PHARMACOTHERAPY, 2019; 20 (18): 2223

Abstract

Introduction: Hereditary transthyretin-mediated amyloidosis (ATTRv; v for variant) is a rare, progressive, fatal multi-systemic disease, autosomal dom......

Full Text Link